Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-002176-39
    Sponsor's Protocol Code Number:V3002401
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-12-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-002176-39
    A.3Full title of the trial
    ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
    ARTEST - Estudio aleatorizado de fase III para evaluar la eficacia y la seguridad del enobosarm en monoterapia frente a un control activo para el tratamiento del cáncer de mama metastásico RA+/RE+/HER2- en pacientes con tinción nuclear del receptor de andrógenos ≥40 % que han presentado una progresión previa de la enfermedad con un con un inhibidor de la aromatasa no esteroideo, fulvestrant y un inhibidor de CDK4/6.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
    ARTEST - Estudio aleatorizado de fase III para evaluar la eficacia y la seguridad del enobosarm en monoterapia frente a un control activo para el tratamiento del cáncer de mama metastásico RA+/RE+/HER2- en pacientes con tinción nuclear del receptor de andrógenos ≥40 % que han presentado una progresión previa de la enfermedad con un con un inhibidor de la aromatasa no esteroideo, fulvestrant y un inhibidor de CDK4/6.
    A.4.1Sponsor's protocol code numberV3002401
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04869943
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVeru Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportVeru Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationVeru Inc.
    B.5.2Functional name of contact pointGary Barnette
    B.5.3 Address:
    B.5.3.1Street Address48 NW 25th St Suite 102
    B.5.3.2Town/ cityMiami
    B.5.3.3Post codeFL 33127
    B.5.3.4CountryUnited States
    B.5.4Telephone number019194263611
    B.5.5Fax numberN/A
    B.5.6E-mailgbarnette@verupharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEnobosarm
    D.3.2Product code VERU-024
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNENOBOSARM
    D.3.9.2Current sponsor codeVERU-024
    D.3.9.4EV Substance CodeSUB182072
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number9
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameExemestane
    D.3.2Product code Exemestane
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEXEMESTANE
    D.3.9.1CAS number 107868-30-4
    D.3.9.3Other descriptive nameEXEMESTANE
    D.3.9.4EV Substance CodeSUB07492MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTamoxifen
    D.3.2Product code Tamoxifen
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTAMOXIFEN
    D.3.9.1CAS number 10540-29-1
    D.3.9.2Current sponsor codeSERM
    D.3.9.3Other descriptive nameSERM
    D.3.9.4EV Substance CodeSUB10825MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameToremifene
    D.3.2Product code Toremifene
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNToremifene
    D.3.9.1CAS number 89778-26-7
    D.3.9.2Current sponsor codeSERM
    D.3.9.3Other descriptive nameSERM
    D.3.9.4EV Substance CodeSUB11197MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEverolimus
    D.3.2Product code Everolimus
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEverolimus
    D.3.9.1CAS number 159351-69-6
    D.3.9.4EV Substance CodeSUB02065MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEverolimus
    D.3.2Product code Everolimus
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEverolimus
    D.3.9.1CAS number 159351-69-6
    D.3.9.4EV Substance CodeSUB02065MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    (AR+)/estrogen receptor positive(ER+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer
    Receptores androgénicos positivos (RA+)/ receptor de estrogeno positivo (RE+)/receptor de factor de crecimiento epidermico humano 2 negativo (HER2-) cancer de pecho metastasico
    E.1.1.1Medical condition in easily understood language
    metastatic breast cancer
    Cancer de mama metastásico
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10027475
    E.1.2Term Metastatic breast cancer
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the efficacy of enobosarm in the treatment of AR+/ER+/HER2- metastatic breast cancer with an AR nuclei staining ≥40% as measured by radiographic progression free survival (rPFS).
    Demostrar la eficacia del enobosarm en el tratamiento del cáncer de mama metastásico (CMM) con receptores androgénicos positivos (RA+) y receptores estrogénicos positivos (RE+), medida en función de la supervivencia sin progresión radiográfica (SSPr)
    E.2.2Secondary objectives of the trial
    1.Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (PR or CR) on study
    2. Duration of response in patients that showed an ORR (PR or CR), treatment responders
    3. Overall Survival (OS)
    4. Change from baseline in Short Physical Performance Battery (SPPB)
    5. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC – QLQ)
    6. Proportion of subjects with Clinical Benefit Response (CBR) defined as a CR (at any time during the study), PR (at any time during the study) or Stable Disease (SD) at Day 180
    1. Tasa de respuestas objetivas (TRO), porcentaje de participantes con una mejor respuesta tumoral de TRO (RP o RC) durante el estudio
    2. Duración de la respuesta en pacientes que mostraron una TRO (RP o RC), con respuesta al tratamiento.
    3. Supervivencia global (SG).
    4. Cambio respecto al inicio del estudio en la batería breve del rendimiento físico (SPPB).
    5. Cambio respecto al inicio del estudio en el Cuestionario de Calidad de Vida (CCV) de la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC).
    6. Proporción de participantes que presentaron una respuesta de beneficio clínico (RBC) definida como una RC (en cualquier momento del
    estudio), RP (en cualquier momento del estudio) o enfermedad estable (EE) el día 180.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Provide informed consent
    2.Be able to communicate effectively with the study personnel
    3.Aged ≥18 years
    4.For Female Subjects: Menopausal status:
    •Be postmenopausal as defined by the National Comprehensive Cancer Network as either:
    -Age ≥55 years and one year or more of amenorrhea
    -Age <55 years and one year or more of amenorrhea, with an estradiol assay <20 pg/mL
    -Age <55 years and surgical menopause with bilateral oophorectomy
    •Be premenopausal or perimenopausal on ovarian suppression with LHRH agonist for at least 4 months, with an estradiol assay <20 pg/mL and a negative urine pregnancy test.
    • If subject is of child bearing potential, the subject must agree to use acceptable methods of contraception:
    -If female study participant could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization of male partner (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository};
    -If female study participant has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
    -If female study participant has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
    •For Male Subjects:
    Subject must agree to use acceptable methods of contraception:
    -If the study subject’s partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
    -If female partner of a study subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
    -If female partner of a study subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used.
    5.For premenopausal and perimenopausal women where exemestane monotherapy or exemestane plus everolimus is chosen as the active control treatment patient must be already on ovarian suppression or to be candidates for this treatment: e.g., luteinizing hormone release hormone agonist or ovariectomy
    6.Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
    7.Documented evidence of ER+/HER2- metastatic breast cancer
    8.Measurable disease is required as per RECIST 1.1 (NOTE: Bone only metastatic disease is acceptable but requires a measurable component)
    9.Have androgen receptor nuclei staining ≥40% as assessed by central laboratory
    10.Received a nonsteroidal AI (monotherapy or combination therapy) either for adjuvant or metastatic breast cancer and fulvestrant (monotherapy or combination therapy) for MBC; at least one of the non-steroidal AI or fulvestrant must have been given in combination with a CDK 4/6 inhibitor.
    11. Previously responded (without disease progression for at least 6 months) to one of the following treatments: fulvestrant monotherapy or fulvestrant plus CDK 4/6 inhibitor or nonsteroidal aromatase inhibitor monotherapy or nonsteroidal aromatase inhibitor plus CDK 4/6 inhibitor for metastatic breast cancer.
    12. Subject is willing to comply with the requirements of the protocol through the end of the study
    1.Proporcionar consentimiento informado
    2.Ser capaz de comunicar efectivamente con el personal del estudio
    3.Edad ≥18años
    4.Para sujetos femeninos:estado menopausia
    •ser postmenopausica como se define en el NCCN (National Comprehensive Cancer Network) como tampoco:
    -Edad ≥55 años y un año o mas de amenorrea
    -Edad <55 years and one year or more of amenorrhea, con un estradio de <20pg/mL
    -Edad >55 años y menopausia quirurgica con ooforectomia bilateral
    • Ser premenopáusicas o perimenopáusicas con supresión ovárica con agonista de LHRH durante al menos 4 meses, con un ensayo de estradiol
    <20 pg / ml y una prueba de embarazo en orina negativa.
    • Si el sujeto está en edad fértil, el sujeto debe aceptar utilizar métodos anticonceptivos aceptables:
    -Si una participante del estudio pudiera quedar embarazada, use métodos anticonceptivos aceptables desde el momento de la primera administración del medicamento del estudio hasta 6 meses después de la administración de la última dosis del medicamento del estudio. Los
    métodos anticonceptivos aceptables son los siguientes: condón con espuma / gel / película / crema / supositorio espermicida [es decir, método anticonceptivo de barrera], esterilización quirúrgica de la pareja masculina (vasectomía con documentación de azoospermia) y un método de barrera {condón usado con espermicida espuma / gel / película / crema / supositorio};
    -Si la participante del estudio se ha sometido a una ligadura de trompas documentada (esterilización femenina), también se debe usar un método de barrera (condón usado con espuma / gel / película / crema / supositorio espermicida)
    -Si la participante del estudio se ha sometido a la colocación documentada de un dispositivo intrauterino (DIU) o sistema intrauterino (SIU), también se debe utilizar un método de barrera (condón con espuma / gel / película / crema / supositorio espermicida)
    • Para sujetos masculinos:
    El sujeto debe aceptar utilizar métodos anticonceptivos aceptables:
    -Si la pareja del sujeto del estudio pudiera quedar embarazada, use métodos anticonceptivos aceptables desde el momento de la primera administración del medicamento del estudio hasta 6 meses después de la administración de la última dosis del medicamento del estudio. Los métodos anticonceptivos aceptables son los siguientes: condón con espuma / gel / película / crema / supositorio espermicida [es decir, método anticonceptivo de barrera], esterilización quirúrgica (vasectomía con documentación de azoospermia) y un método de barrera {condón usado con espuma / gel espermicida / película / crema / supositorio}, la pareja femenina usa anticonceptivos orales (píldoras combinadas de estrógeno / progesterona), progesterona inyectable o implantes subdérmicos y un método de barrera (condón usado con espuma / gel / película / crema / supositorio espermicida)
    -Si la pareja femenina de un sujeto de estudio se ha sometido a una ligadura de trompas documentada (esterilización femenina), también se debe usar un método de barrera (condón usado con espuma / gel / película / crema / supositorio espermicida) -Si la pareja femenina de un sujeto de estudio se ha sometido a la colocación documentada de un dispositivo intrauterino (DIU) o sistema intrauterino (SIU), también se debe usar un método de barrera (condón con espuma / gel / película / crema / supositorio espermicida) Estado funcional del Grupo Oncológico Cooperativo del Este (ECOG) de ≤2
    6.Evidencia documentada de cáncer de mama metastásico ER + / HER2- 7.Se requiere enfermedad medible según RECIST 1.1 (NOTA: la
    enfermedad metastásica solo ósea es aceptable pero requiere un componente medible)
    8.Tienen tinción de núcleos de receptores de andrógenos ≥40% según lo evaluado por el laboratorio central
    9. Recibió un IA no esteroideo (monoterapia o terapia combinada) para cáncer de mama adyuvante o metastásico y fulvestrant (monoterapia o
    terapia combinada) para MBC; al menos uno de los IA no esteroides o fulvestrant debe haberse administrado en combinación con un inhibidor
    de CDK 4/6.
    10. Respondieron previamente (sin progresión de la enfermedad durante al menos 6 meses) a uno de los siguientes tratamientos: monoterapia
    con fulvestrant o fulvestrant más inhibidor de CDK 4/6 o monoterapia con inhibidor de aromatasa no esteroideo o inhibidor de aromatasa no esteroideo más inhibidor de CDK 4/6 para cáncer de mama metastásico .
    11. El sujeto está dispuesto a cumplir con los requisitos del protocolo
    hasta el final del estudio.
    E.4Principal exclusion criteria
    1. Known hypersensitivity or allergy to enobosarm
    2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 X upper limit of normal (ULN) or total bilirubin >ULN (an elevated total bilirubin up to 1.5 X ULN attributed to a previously confirmed diagnosis of Gilbert’s disease is acceptable if all other eligibility criteria are met). In patients with documented metastases to the liver, the limits for inclusion are ALT or AST >5.0 X ULN or total bilirubin >1.5 X ULN.
    3. Patients with biliary catheter
    4. Creatinine clearance < 30 mL/min as measured using the Cockcoft Gault formula (patients with mild and moderate renal failure are not excluded from participation in this study)
    5. Previously received >1 course of chemotherapy (not including immunotherapies or targeted therapies) for the treatment of metastatic breast cancer.
    NOTE: A course of systemic chemotherapy is defined as a line of prior chemotherapy. Chemotherapy received in the neoadjuvant or adjuvant setting will not count as a prior line of chemotherapy.
    6. Subjects with radiographic evidence of central nervous system (CNS) metastases as assessed by CT or MRI that are not well-controlled (symptomatic or requiring control with continuous corticosteroid therapy [e.g., dexamethasone])
    Note: Subjects with CNS metastases are permitted to participate in the study if the CNS metastases are medically well-controlled and stable for at least 30 days after receiving local therapy (irradiation, surgery, etc.)
    7. Radiotherapy within 14 days prior to randomization except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization
    8. Any comorbid disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, severe renal impairment, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk
    9. Treatment with any investigational product within < 4 half-lives for each individual investigational product OR within 30 days prior to randomization
    10. Major surgery within 30 days prior to randomization
    11. Treatment with testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (enzalutamide, abiraterone, bicalutamide, apalutamide, or darolutamide). Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the Medical Monitor) or any other androgenic agent.
    12. Treatment with any of the following hormone replacement therapies for metastatic breast cancer. Prior use in the adjuvant or neoadjuvant setting is allowed if the treatment is discontinued greater than 30 days prior to randomization: Estrogens, Megesterol acetate, Testosterone
    13. All other concurrent anticancer treatments (including, but not limited to, all SERMs unless randomized to the Control Treatment Group with a SERM as the control treatment, AIs unless randomized to Control Treatment Group (exemestane or exemestane plus everolimus) with the AI containing treatment as the control treatment, and all CDK 4/6 inhibitors)
    14.An abnormal ECG result which, based on the investigator’s clinical judgment, would place the subject at increased risk
    15. Has a known additional, invasive, malignancy that is progressing or required active treatment in the last 5 years [note: subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal breast carcinoma in situ, bladder cancer (superficial treated), or cervical carcinoma in situ that have undergone potentially curative therapy are not excluded]
    16. Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of study treatment
    1. Hipersensibilidad o alergia conocidas al enobosarm
    2. Alanina aminotransferasa (ALT) o aspartato aminotransferasa (AST)>2.5 X límite superior de normalidad (LSN) o bilirrubina total> LSN (una bilirrubina total elevada hasta 1.5 X LSN atribuida a un diagnóstico previamente confirmado de enfermedad de Gilbert es aceptable si se cumplen todos los demás criterios de elegibilidad). En pacientes con metástasis hepáticas documentadas, los límites de inclusión son ALT o
    AST> 5,0 X LSN o bilirrubina total> 1,5 X LSN.
    3. Pacientes con catéter biliar.
    4. Aclaramiento de creatinina <30 ml / min medido con la fórmula de Cockcoft Gault (los pacientes con insuficiencia renal leve y moderada no
    están excluidos de la participación en este estudio)
    5. Recibió previamente> 1 ciclo de quimioterapia (sin incluir inmunoterapias o terapias dirigidas) para el tratamiento del cáncer de
    mama metastásico.NOTA: Es posible que los sujetos hayan recibido 1 curso de quimioterapia en el entorno adyuvante o neoadyuvante que no se
    consideraría una línea de terapia.
    6. Sujetos con evidencia radiográfica de metástasis en el sistema nervioso central (SNC) evaluados por CT o MRI que no están bien
    controlados (sintomáticos o que requieren control con tratamiento continuo con corticosteroides [p. Ej., Dexametasona])
    Nota: Los sujetos con metástasis en el SNC pueden participar en el estudio si las metástasis en el SNC están médicamente bien controladas
    y son estables durante al menos 30 días después de recibir la terapia local (irradiación, cirugía, etc.)
    7. Radioterapia dentro de los 14 días anteriores a la aleatorización, excepto en el caso de radioterapia localizada con fines analgésicos o
    para lesiones líticas con riesgo de fractura, que luego se puede completar dentro de los 7 días anteriores a la aleatorización. Los sujetos deben haberse recuperado de los efectos tóxicos de la radioterapia antes de la aleatorización.
    8. Cualquier enfermedad o afección comórbida (médica o quirúrgica) que pueda comprometer el sistema nervioso central, hepático, hematológico,
    cardiovascular, endocrino, pulmonar, renal, gastrointestinal o central; u otras condiciones que puedan interferir con la absorción, distribución,
    metabolismo o excreción del fármaco del estudio, o que pondrían al sujeto en mayor riesgo
    9. Tratamiento con cualquier producto en investigación dentro de <4 semividas para cada producto en investigación individual O dentro de los 30 días anteriores a la aleatorización
    10. Cirugía mayor en los 30 días anteriores a la aleatorización.
    11. Tratamiento con testosterona, metiltestosterona, oxandrolona (Oxandrin®), oximetolona, danazol, fluoximesterona (Halotestin®), agentes similares a la testosterona (como dehidroepiandrosterona, androstenediona y otros compuestos androgénicos, incluidos los herbáceos) o antiandrógenos (enzalutamida, abiraterona , bicalutamida, apalutamida o darolutamida). La terapia previa con testosterona y agentes similares a la testosterona es aceptable con un período de lavado de 30 días (si la terapia previa con testosterona fue de depósito a largo plazo en los últimos 6 meses, el sitio debe comunicarse con el Monitor médico) o cualquier otro agente androgénico.
    12. Tratamiento con cualquiera de las siguientes terapias de reemplazo hormonal para el cáncer de mama metastásico. Se permite el uso previo en el entorno adyuvante o neoadyuvante si el tratamiento se suspende más de 30 días antes de la aleatorización: estrógenos, acetato de megesterol, testosterona.
    13. Todos los demás tratamientos contra el cáncer concurrentes (incluidos, entre otros, todos los SERM a menos que se hayan
    aleatorizado al Grupo de tratamiento de control con un SERM como tratamiento de control, IA a menos que se hayan aleatorizado al Grupo
    de tratamiento de control (exemestano o exemestano más everolimus) con el AI que contenga tratamiento como tratamiento de control y todos
    los inhibidores de CDK 4/6).
    14.Un resultado de ECG anormal que, según el juicio clínico del investigador, colocaría al sujeto en mayor riesgo.
    15. Tiene una neoplasia maligna invasiva adicional conocida que está progresando o requirió tratamiento activo en los últimos 5 años [nota:
    sujetos con carcinoma de células basales de piel, carcinoma de células escamosas de piel, carcinoma ductal de mama in situ, cáncer de vejiga
    (superficial tratado), o carcinoma cervical in situ que se han sometido a una terapia potencialmente curativa no se excluyen]
    16. Está embarazada, amamantando o amamantando, o tiene la intención de quedar embarazada durante el estudio o dentro de los 60 días posteriores a la dosis final del tratamiento del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group. Progression will be defined based on RECIST 1.1.
    El criterio de valoración principal del estudio es la mediana de la supervivencia libre de progresión radiográfica (SSpr) en el grupo de tratamiento con Enobosarm en comparación con el grupo de tratamiento de control. La progresión se definirá en base a RECIST 1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    From the time of randomization to objective tumor progression or death as defined by RECIST 1.1 for progressive disease and summarized using a Kaplan-Meier curve. The final analysis will occur when 136 events occur in the study population.
    Desde el momento de la aleatorización hasta la progresión objetiva del tumor o la muerte según lo definido por RECIST 1.1 para la enfermedad
    progresiva y resumido mediante una curva de Kaplan-Meier. El análisis final ocurrirá cuando ocurran 136 eventos en la población de estudio.
    E.5.2Secondary end point(s)
    1. Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (PR or CR) on study
    2. Duration of response in patients that showed an ORR (PR or CR), treatment responders
    3. Overall Survival (OS)
    4. Change from baseline in Short Physical Performance Battery (SPPB)
    5. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC – QLQ)
    6. Proportion of subjects with Clinical Benefit Response (CBR) at Day 180
    1.Tasa de respuestas objetivas (TRO), porcentaje de participantes con una mejor respuesta tumoral de TRO (RP o RC) durante el estudio
    2. Duración de la respuesta en pacientes que mostraron una TRO (RP o RC), pacientes con respuesta al tratamiento
    3. Supervivencia global (SG)
    4. Cambio respecto al inicio del estudio en la batería breve del rendimiento físico (SPPB)
    5. Cambio respecto al inicio del estudio en el Cuestionario de Calidad de Vida (CCV) de la Organización Europea para la Investigación y el
    Tratamiento del Cáncer (EORTC)
    6. Proporción de participantes que presentaron una respuesta de beneficio clínico (RBC) el día 180
    E.5.2.1Timepoint(s) of evaluation of this end point
    The final analysis will occur when 136 events occur in the study population.
    El análisis final ocurrirá cuando ocurran 136 eventos en la población de estudio.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Poland
    Spain
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 140
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 70
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 48
    F.4.2.2In the whole clinical trial 210
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects will continue study treatment until disease progression confirmed by blinded independent central reader (BICR) is observed. A safety follow up visit will occur approximately 30 days after last dose of study drug. Thereafter, survival follow up will completed monthly for one year. Suvival follow up may be completed by phone or records review. After one year, survival follow up will be completed every 90 days.
    Los sujetos continuarán el tratamiento de estudio hasta la progresión de la enfermedad confirmada por el lector central indep ciego (BICR).
    Se realizará visita de seguimiento de seguridad aprox. 30 días después de la última dosis del fármaco del estudio. Desde entonces, el seguimiento de supervivencia sera mensualmente durante un año. El
    seguimiento de supervivencia se puede hacer por teléfono o revisión de registros. Tras un año, el seguimiento de supervivencia se completará cada 90 días.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-12-22
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:06:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA